Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

  • A. Michael Lincoff
  • Eric J. Topol

Part of the Contemporary Cardiology book series (CONCARD)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Basic Principles

    1. Front Matter
      Pages 1-1
    2. Thaddeus R. Tolleson, Robert A. Harrington
      Pages 3-20
    3. Edward F. Plow
      Pages 21-34
  3. Glycoprotein IIb/IIIa Blockade During Coronary Intervention

    1. Front Matter
      Pages 91-91
    2. Conor O’Shea, James E. Tcheng
      Pages 115-126
    3. Mahomed Y. Salame, Spencer B. King III, Nicolas A. Chronos
      Pages 127-142
    4. Marcel J. B. M. van den Brand, Maarten L. Simoons
      Pages 143-168
    5. A. Michael Lincoff, Eric J. Topol
      Pages 169-197
  4. Glycoprotein IIb/IIIa Blockade for Acute Ischemic Syndromes

    1. Front Matter
      Pages 199-199
    2. David J. Moliterno, Harvey D. White
      Pages 201-227
    3. Adam B. Greenbaum, Robert A. Harrington, E. Magnus Ohman
      Pages 229-249
  5. Practical Issues and Future Applications

    1. Front Matter
      Pages 251-251
    2. Daniel B. Mark
      Pages 253-266
    3. Neal S. Kleiman, Wojciech Mazur, Nikki Graziadei
      Pages 267-285
    4. Dean J. Kereiakes, Christopher P. Cannon
      Pages 287-314
    5. Robert M. Califf, David F. Kong
      Pages 327-360
  6. Back Matter
    Pages 361-369

About this book


In Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, the major investigators working in this rapidly advancing field join together under the aegis of A. Michael Lincoff and Eric J. Topol to provide the first comprehensive overview of the preclinical and clinical development of the glycoprotein IIb/IIIa receptor antagonists. These acknowledged experts elucidate the theoretical basis for the inhibition of platelet aggregation in the treatment of coronary syndromes, present and synthesize evidence for the efficacy of glycoprotein IIb/IIIa blockade in inhibiting ischemic complications of both coronary intervention and acute coronary syndromes, and provide guidelines for the use of this novel class of agents in the clinical management of cardiovascular disease. They also compare the pharmacology and clinical efficacy of the currently available glycoprotein IIb/IIIa receptor inhibitors and speculate about further potential applications of these agents in the treatment of vascular disease.
Written by the scientists and physicians who discovered and characterized this important new class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers the most complete and authoritative review of these powerful new therapeutics available today.


Stent cardiovascular cardiovascular disease clinical trial vascular disease

Editors and affiliations

  • A. Michael Lincoff
    • 1
    • 2
  • Eric J. Topol
    • 2
    • 3
  1. 1.Experimental Interventional Laboratory, Joseph J. Jacobs Center for Thrombosis and Vascular BiologyThe Cleveland Clinic FoundationClevelandUSA
  2. 2.Department of CardiologyThe Cleveland Clinic FoundationClevelandUSA
  3. 3.Joseph J. Jacobs Center for Thrombosis and Vascular BiologyThe Cleveland Clinic FoundationClevelandUSA

Bibliographic information